Skip to main content

Table 3 The association of the combination of SHR and GV with mortality in patients with or without diabetes

From: Simultaneous assessment of stress hyperglycemia ratio and glycemic variability to predict mortality in patients with coronary artery disease: a retrospective cohort study from the MIMIC-IV database

 

Group

Low SHR and low GV

(SHR < 1.16 and GV < 27.3)

High SHR and low GV

(SHR > 1.16 and GV < 27.3)

Low SHR and high GV

(SHR < 1.16 and GV > 27.3)

High SHR and high GV

(SHR > 1.16 and GV > 27.3)

In-hospital mortality

Overall

 Unadjusted

1.000

3.520 (2.163–5.731)‡

1.734 (0.975–3.081)

5.984 (3.743–9.567)‡

  Model 1

1.000

4.664 (2.656–8.190)‡

1.553 (0.770–3.131)

8.416 (4.862–14.568)‡

  Model 2

1.000

3.694 (1.979–6.898)‡

1.447 (0.685–3.056)

5.436 (2.921–10.118)‡

  Model 4

1.000

3.582 (1.917–6.694)‡

1.407 (0.667–2.967)

5.163 (2.768–9.630)‡

Patients without diabetes

 Unadjusted

1.000

3.956 (2.039–7.678)‡

3.040 (1.155–7.999)*

14.050 (7.343–26.884)‡

  Model 1

1.000

5.508 (2.524–12.024)‡

4.098 (1.447–11.604)†

20.024 (9.313–43.052)‡

  Model 2

1.000

4.347 (1.823–10.369)‡

3.294 (1.057–10.271)*

10.831 (4.494–26.105)‡

  Model 4

1.000

4.387 (1.836–10.482)‡

3.280 (1.046–10.282)*

11.302 (4.593–27.813)‡

Patients with diabetes

 Unadjusted

1.000

3.166 (1.531–6.551)†

1.121 (0.535–2.351)

2.512 (1.254–5.032)†

  Model 1

1.000

4.111 (1.791–9.433)‡

0.757 (0.290–1.979)

3.307 (1.463–7.475)†

  Model 2

1.000

4.221 (1.542–11.558)†

0.988 (0.343–2.845)

3.664 (1.365–9.830)†

  Model 4

1.000

4.234 (1.522–11.779)†

0.913 (0.314–2.653)

3.714 (1.364–10.113)*

1-year mortalitya

Overall

 Unadjusted

1.000

2.243 (1.702–2.957)‡

1.680 (1.215–2.324)†

3.336 (2.372–4.692)‡

  Model 1

1.000

3.024 (2.184–4.187)‡

2.137 (1.454–3.140)‡

4.667 (3.088–7.051)‡

  Model 3

1.000

2.121 (1.512–2.975)‡

1.980 (1.322–2.966)‡

2.975 (1.932–4.579)‡

  Model 5

1.000

2.029 (1.443–2.852)‡

1.887 (1.259–2.829)†

2.861 (1.859–4.402)‡

Patients without diabetes

 Unadjusted

1.000

2.193 (1.492–3.222)‡

3.404 (2.025–5.722)‡

5.998 (3.704–9.714)‡

  Model 1

1.000

3.272 (2.066–5.183)‡

4.770 (2.614–8.705)‡

9.336 (5.248–16.605)‡

  Model 3

1.000

2.409 (1.492–3.891)‡

3.975 (2.129–7.422)‡

5.830 (3.175–10.702)‡

  Model 5

1.000

2.243 (1.381–3.641)†

3.951 (2.124–7.351)‡

5.169 (2.806–9.521)‡

Patients with diabetes

 Unadjusted

1.000

2.589 (1.727–3.880)‡

1.059 (0.685–1.636)

2.003 (1.223–3.279)†

  Model 1

1.000

3.170 (1.975–5.088)‡

1.158 (0.688–1.949)

2.391 (1.304–4.382)†

  Model 3

1.000

2.013 (1.224–3.311)†

1.343 (0.787–2.294)

1.804 (0.962–3.382)

  Model 5

1.000

2.006 (1.218–3.303)†

1.309 (0.765–2.239)

1.837 (0.978–3.451)

  1. Abbreviations: GV, glycemic variability; SHR, stress hyperglycemia ratio
  2. aThe assumption of proportional hazards was not met. Therefore, HRs were calculated using Cox regression analysis with time-dependent covariates
  3. Model 1: adjusted for age, female, and body mass index
  4. Model 2: adjusted for Model 1 plus heart rate, acute myocardial infarction, chronic heart failure, peripheral vascular disease, cerebrovascular disease, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, vasoactive drugs, insulin, other antidiabetic drugs, renal replacement therapy, ventilation, and estimated glomerular filtration rate
  5. Model 3: adjusted for Model 1 plus diastolic blood pressure, heart rate, acute myocardial infarction, hypertension, diabetes, chronic heart failure, peripheral vascular disease, cerebrovascular disease, antiplatelets, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, insulin, other antidiabetic drugs, renal replacement therapy, ventilation, and estimated glomerular filtration rate
  6. Model 4 (sensitivity analysis): adjusted for Model 2 plus the Sequential Organ Failure Assessment score
  7. Model 5 (sensitivity analysis): adjusted for Model 3 plus the Sequential Organ Failure Assessment score
  8. *P < 0.05, †P < 0.01, ‡P < 0.001